StreetInsider.com News Articles

Form 8-K Silo Pharma, Inc. For: Jun 01

Wed, 03 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260603/26600086.html

Form 8-K Silo Pharma, Inc. For: Jun 01

Wed, 03 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260603/26600086.html

Form 8-K Silo Pharma, Inc. For: Jun 01

Mon, 01 Jun 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260601/26580379.html

Form 8-K Silo Pharma, Inc. For: Jun 01

Mon, 01 Jun 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260601/26580379.html

Form 10-Q Silo Pharma, Inc. For: Mar 31

Thu, 14 May 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260514/26489051.html

Form 10-Q Silo Pharma, Inc. For: Mar 31

Thu, 14 May 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260514/26489051.html

Silo Pharma files patent for ibogaine treatment targeting brain injury

Thu, 07 May 2026 08:06:40 -0400

Silo Pharma (NASDAQ: SILO) filed a provisional patent application with the United States Patent and Trademark Office for ibogaine-based therapeutics to treat traumatic brain injury and related neuropsychiatric conditions, according to a company statement.

The patent application, titled "Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine," covers the use of ibogaine and related compounds for treating TBI, post-traumatic stress disorder and associated conditions.

The filing aligns with an Executive Order by President Trump announced April 18, 2026, under which the FDA granted Breakthrough Therapy designation to specific psychedelic drugs through a program designed to expedite development

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Thu, 07 May 2026 08:05:00 -0400

New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines

Silo Pharma targets unmet need in a drug market with no FDA-approved therapies that address structural or regenerative aspects of traumatic brain injury

Traumatic brain injury therapeutics market estimated to reach $6 billion by 2032

SARASOTA, FLA., May 07, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced a strategic initiative to explore ibogaine-based therapeutics for the treatment of

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Thu, 07 May 2026 08:05:00 -0400

New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines

Silo Pharma targets unmet need in a drug market with no FDA-approved therapies that address structural or regenerative aspects of traumatic brain injury

Traumatic brain injury therapeutics market estimated to reach $6 billion by 2032

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Thu, 07 May 2026 08:05:00 -0400

New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines

Silo Pharma targets unmet need in a drug market with no FDA-approved therapies that address structural or regenerative aspects of traumatic brain injury

Traumatic brain injury therapeutics market estimated to reach $6 billion by 2032

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Thu, 07 May 2026 08:05:00 -0400

New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines

Silo Pharma targets unmet need in a drug market with no FDA-approved therapies that address structural or regenerative aspects of traumatic brain injury

Traumatic brain injury therapeutics market estimated to reach $6 billion by 2032

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Thu, 07 May 2026 08:05:00 -0400

New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines

Silo Pharma targets unmet need in a drug market with no FDA-approved therapies that address structural or regenerative aspects of traumatic brain injury

Traumatic brain injury therapeutics market estimated to reach $6 billion by 2032

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Thu, 07 May 2026 08:05:00 -0400

New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines

Silo Pharma targets unmet need in a drug market with no FDA-approved therapies that address structural or regenerative aspects of traumatic brain injury

Traumatic brain injury therapeutics market estimated to reach $6 billion by 2032

Silo Pharma comments on federal psychedelic therapy initiatives

Wed, 29 Apr 2026 09:08:45 -0400

Silo Pharma Inc. (NASDAQ: SILO) issued a statement regarding recent federal actions aimed at advancing psychedelic-based therapeutics for mental health and substance use disorders. The company said these initiatives validate its approach to treating neurological and psychiatric conditions.

The Advanced Research Projects Agency for Health announced initial awardees under its EVIDENT program, including Johns Hopkins University and other institutions focused on psychedelic science. The Food and Drug Administration granted investigational new drug clearance to DemeRx NB for its noribogaine candidate targeting alcohol use disorder.

The FDA issued three Commissioner's National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics. The agency

Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD